CAPTRUST Financial Advisors
RNAZ icon

CAPTRUST Financial Advisors’s TransCode Therapeutics RNAZ Stock Holding History

CAPTRUST Financial Advisors’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18
Closed -$9.28K – 2383
2024
Q3 		$9.28K Buy
18
+6
+50% +$2.43K ﹤0.01% 2274
2024
Q2 		$11.3K Buy
+12
New +$10.7K ﹤0.01% 2184
2024
Q1 		– Sell
-1
Closed -$8.24K – 2563
2023
Q4 		$8.24K Buy
+1
New +$11.2K ﹤0.01% 2635

Other funds holding RNAZ

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

CAPTRUST Financial Advisors's RNAZ Position: Q4 2024 in Review

CAPTRUST Financial Advisors sold out of TransCode Therapeutics (RNAZ) in Q4 2024, closing a stake of 18 shares — an estimated $9.28K sold.

CAPTRUST Financial Advisors first reported a position in RNAZ in Q4 2023 and held it in 3 quarters. The position peaked at $11.3K in Q2 2024. 3 funds tracked by Wall St. Rank hold RNAZ as of Q4 2024.

  • CAPTRUST Financial Advisors reported no remaining TransCode Therapeutics position as of Q4 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 18 TransCode Therapeutics shares in Q4 2024, an estimated $9.28K.
  • CAPTRUST Financial Advisors first reported a position in TransCode Therapeutics in Q4 2023 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's TransCode Therapeutics position peaked at $11.3K in Q2 2024.
  • 3 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q4 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.